# Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants

> **NCT03934541** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 24 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** MPER-656 Liposome Vaccine
- **BIOLOGICAL:** Placebo for MPER-656 Liposome Vaccine

## Key facts

- **NCT ID:** NCT03934541
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-26
- **Primary completion:** 2021-02-05
- **Final completion:** 2021-05-26
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03934541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03934541, "Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03934541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*